Alemtuzumab Use In Relapsed and Refractory Chronic Lymphocytic Leukemia

被引：6
作者：
Arnason, Jon E. [1 ,2 ]
Brown, Jennifer R. [1 ,3 ]
机构：
[1] Harvard Univ, Sch Med, Boston, MA USA
[2] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[3] DFCI, CLL Ctr, Boston, MA USA
来源：
HEMATOLOGY-AMERICAN SOCIETY HEMATOLOGY EDUCATION PROGRAM | 2011年
关键词：
D O I：
10.1182/asheducation-2011.1.119
中图分类号：
G40 [教育学];
学科分类号：
040101 ; 120403 ;
摘要：
A 62-year-old woman with chronic lymphocytic leukemia (CLL) who initially presented with lymphocytosis and 13q deletion in 1996 now presents to the clinic for recommendations regarding relapsed disease. The patient has received multiple prior therapies, including single-agent fludarabine, fludarabine and rituximab, and bendamustine and rituximab. She now has recurrent lymphocytosis with a WBC count that has increased from 13 000 2 months ago to 115 000 today and a platelet count of 55 000 but no lymphadenopathy. In addition, your evaluation finds that she has acquired a 17p deletion.
引用
收藏
页码：119 / 120
页数：2
相关论文
共 13 条
  • [1] Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study
    Cortelezzi, A.
    Pasquini, M. C.
    Gardellini, A.
    Gianelli, U.
    Bossi, A.
    Reda, G.
    Sarina, B.
    Musto, P.
    Barcellini, W.
    Neri, A.
    Deliliers, G. L.
    [J]. LEUKEMIA, 2009, 23 (11) : 2027 - 2033
  • [2] P53 GENE DELETION PREDICTS FOR POOR SURVIVAL AND NONRESPONSE TO THERAPY WITH PURINE ANALOGS IN CHRONIC B-CELL LEUKEMIAS
    DOHNER, H
    FISCHER, K
    BENTZ, M
    HANSEN, K
    BENNER, A
    CABOT, G
    DIEHL, D
    SCHLENK, R
    COY, J
    STILGENBAUER, S
    VOLKMANN, M
    GALLE, PR
    POUSTKA, A
    HUNSTEIN, W
    LICHTER, P
    [J]. BLOOD, 1995, 85 (06) : 1580 - 1589
  • [3] Phase II study of alerntuzurnab in chronic lymphoproliferative disorders
    Ferrajoli, A
    O'Brien, SM
    Cortes, JE
    Giles, FJ
    Thomas, DA
    Faderl, S
    Kurzrock, R
    Lerner, S
    Kontoyiannis, DP
    Keating, MJ
    [J]. CANCER, 2003, 98 (04) : 773 - 778
  • [4] Golay J, 2004, HAEMATOLOGICA, V89, P1476
  • [5] Disease activity and pretreatment, rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemia
    Hensel, M
    Kornacker, M
    Yammeni, S
    Egerer, G
    Ho, AD
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2003, 122 (04) : 600 - 606
  • [6] Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia
    Hillmen, Peter
    Skotnicki, Aleksander B.
    Robak, Tadeusz
    Jaksic, Branimir
    Dmoszynska, Anna
    Wu, Jingyang
    Sirard, Cynthia
    Mayer, Jiri
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (35) : 5616 - 5623
  • [7] Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia
    Karlsson, Claes
    Lundin, Jeanette
    Kimby, Eva
    Kennedy, Ben
    Moreton, Paul
    Hillmen, Peter
    Osterborg, Anders
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2009, 144 (01) : 78 - 85
  • [8] Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study
    Keating, MJ
    Flinn, I
    Jain, V
    Binet, JL
    Hillmen, P
    Byrd, J
    Albitar, M
    Brettman, L
    Santabarbara, P
    Wacker, B
    Rai, KR
    [J]. BLOOD, 2002, 99 (10) : 3554 - 3561
  • [9] Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia
    Osterborg, A
    Dyer, MJS
    Bunjes, D
    Pangalis, GA
    Bastion, Y
    Catovsky, D
    Mellstedt, H
    Rankin, E
    Tsekouras, C
    Pangalis, GA
    Cavalli, F
    Sessa, C
    Huhn, D
    Marcus, R
    Maughan, T
    Poynton, C
    Nissen, N
    Carney, D
    Brittinger, G
    Uppenkamp, M
    Elonen, E
    Teerenhovi, L
    Engert
    Willemze, R
    KluinNelemans, J
    Thomas, J
    Epenetos, AA
    Nethersell, A
    Dyer, M
    Catovsky, D
    Dicato, M
    Bastion, Y
    Coiffier, B
    Ranada, JMF
    Crowther, D
    Woll, P
    Raemakaers, J
    dePauw, B
    Degos, L
    Gissellbrecht
    Reiffers, J
    Mellstedt, H
    Fassas, A
    Anagnostopoulos, A
    Bunjes, D
    Jaeger, U
    Stahel, RA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (04) : 1567 - 1574
  • [10] Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia
    Osterborg, A.
    Foa, R.
    Bezares, R. F.
    Dearden, C.
    Dyer, M. J. S.
    Geisler, C.
    Lin, T. S.
    Montillo, M.
    van Oers, M. H. J.
    Wendtner, C-M
    Rai, K. R.
    [J]. LEUKEMIA, 2009, 23 (11) : 1980 - 1988
12